User profiles for AA Sahin
Aysegul SahinMD Anderson Cancer Center Verified email at mdanderson.org Cited by 51511 |
[PDF][PDF] Benign breast diseases: classification, diagnosis, and management
M Guray, AA Sahin - The oncologist, 2006 - Wiley Online Library
… Correspondence: Aysegul Sahin, MD, University of Texas MD Anderson Cancer Center,
Unit 85, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Telephone: 713-794-1500; …
Unit 85, 1515 Holcombe Boulevard, Houston, Texas 77030, USA. Telephone: 713-794-1500; …
Carcinoma of the male breast
IA Jaiyesimi, AU Buzdar, AA Sahin… - Annals of internal …, 1992 - acpjournals.org
▪ The natural history and current management of carcinoma of the breast in men is reviewed.
Articles published from 1942 to 1992 on the natural history, clinical manifestations, …
Articles published from 1942 to 1992 on the natural history, clinical manifestations, …
Neoadjuvant chemotherapy for breast carcinoma: multidisciplinary considerations of benefits and risks
…, KK Hunt, GJ Whitman, AA Sahin… - … Journal of the …, 2003 - Wiley Online Library
BACKGROUND The majority of patients with breast carcinoma receive chemotherapy as a
component of multimodality treatment. Over the past decade, it has become increasingly …
component of multimodality treatment. Over the past decade, it has become increasingly …
[HTML][HTML] PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
The ErbB2-targeting antibody, trastuzumab (Herceptin), has remarkable therapeutic efficacy
in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate…
in certain patients with ErbB2-overexpressing tumors. The overall trastuzumab response rate…
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized …
…, TL Smith, KK Hunt, SE Singletary, AA Sahin… - Journal of clinical …, 2005 - ascopubs.org
Purpose The objective of this study was to determine whether the addition of trastuzumab to
chemotherapy in the neoadjuvant setting could increase pathologic complete response (…
chemotherapy in the neoadjuvant setting could increase pathologic complete response (…
Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth
The development of life-threatening cancer metastases at distant organs requires
disseminated tumour cells’ adaptation to, and co-evolution with, the drastically different …
disseminated tumour cells’ adaptation to, and co-evolution with, the drastically different …
[HTML][HTML] Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity
Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell
death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the …
death protein-1 (PD-1) leads to tumour-associated immune escape. Here we show that the …
[HTML][HTML] IKKβ suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway
TNFα has recently emerged as a regulator linking inflammation to cancer pathogenesis, but
the detailed cellular and molecular mechanisms underlying this link remain to be elucidated. …
the detailed cellular and molecular mechanisms underlying this link remain to be elucidated. …
ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation
The RAS–ERK pathway is known to play a pivotal role in differentiation, proliferation and
tumour progression. Here, we show that Erk downregulates Forkhead box O 3a (FOXO3a) by …
tumour progression. Here, we show that Erk downregulates Forkhead box O 3a (FOXO3a) by …
[PDF][PDF] Deubiquitination and stabilization of PD-L1 by CSN5
Pro-inflammatory cytokines produced in the tumor microenvironment lead to eradication of
anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified …
anti-tumor immunity and enhanced tumor cell survival. In the current study, we identified …